430 related articles for article (PubMed ID: 21828272)
21. Monensin, a novel potent MYB inhibitor, suppresses proliferation of acute myeloid leukemia and adenoid cystic carcinoma cells.
Yusenko MV; Trentmann A; Andersson MK; Ghani LA; Jakobs A; Arteaga Paz MF; Mikesch JH; Peter von Kries J; Stenman G; Klempnauer KH
Cancer Lett; 2020 Jun; 479():61-70. PubMed ID: 32014461
[TBL] [Abstract][Full Text] [Related]
22. C/EBPβ sustains the oncogenic program of AML cells by cooperating with MYB and co-activator p300 in a transcriptional module.
Klempnauer KH
Exp Hematol; 2022 Apr; 108():8-15. PubMed ID: 35032593
[TBL] [Abstract][Full Text] [Related]
23. Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model.
Liu Q; Chen L; Atkinson JM; Claxton DF; Wang HG
Cell Death Dis; 2016 Sep; 7(9):e2361. PubMed ID: 27607576
[TBL] [Abstract][Full Text] [Related]
24. shRNA screening identifies JMJD1C as being required for leukemia maintenance.
Sroczynska P; Cruickshank VA; Bukowski JP; Miyagi S; Bagger FO; Walfridsson J; Schuster MB; Porse B; Helin K
Blood; 2014 Mar; 123(12):1870-82. PubMed ID: 24501218
[TBL] [Abstract][Full Text] [Related]
25. In vitro transformation of primary human CD34+ cells by AML fusion oncogenes: early gene expression profiling reveals possible drug target in AML.
Abdul-Nabi AM; Yassin ER; Varghese N; Deshmukh H; Yaseen NR
PLoS One; 2010 Aug; 5(8):e12464. PubMed ID: 20805992
[TBL] [Abstract][Full Text] [Related]
26. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia.
Somervaille TC; Cleary ML
Cancer Cell; 2006 Oct; 10(4):257-68. PubMed ID: 17045204
[TBL] [Abstract][Full Text] [Related]
27. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
Chu Y; Chen Y; Guo H; Li M; Wang B; Shi D; Cheng X; Guan J; Wang X; Xue C; Cheng T; Shi J; Yuan W
Oncogene; 2020 Dec; 39(50):7239-7252. PubMed ID: 33037410
[TBL] [Abstract][Full Text] [Related]
28. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
29. The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;Nras(G12D) acute myeloid leukemia.
Shi J; Wang E; Zuber J; Rappaport A; Taylor M; Johns C; Lowe SW; Vakoc CR
Oncogene; 2013 Feb; 32(7):930-8. PubMed ID: 22469984
[TBL] [Abstract][Full Text] [Related]
30. EVI1 is critical for the pathogenesis of a subset of MLL-AF9-rearranged AMLs.
Bindels EM; Havermans M; Lugthart S; Erpelinck C; Wocjtowicz E; Krivtsov AV; Rombouts E; Armstrong SA; Taskesen E; Haanstra JR; Beverloo HB; Döhner H; Hudson WA; Kersey JH; Delwel R; Kumar AR
Blood; 2012 Jun; 119(24):5838-49. PubMed ID: 22553314
[TBL] [Abstract][Full Text] [Related]
31. MLL-AF9 Expression in Hematopoietic Stem Cells Drives a Highly Invasive AML Expressing EMT-Related Genes Linked to Poor Outcome.
Stavropoulou V; Kaspar S; Brault L; Sanders MA; Juge S; Morettini S; Tzankov A; Iacovino M; Lau IJ; Milne TA; Royo H; Kyba M; Valk PJM; Peters AHFM; Schwaller J
Cancer Cell; 2016 Jul; 30(1):43-58. PubMed ID: 27344946
[TBL] [Abstract][Full Text] [Related]
32. MYB-activated models for testing therapeutic agents in adenoid cystic carcinoma.
Jiang Y; Gao R; Cao C; Forbes L; Li J; Freeberg S; Fredenburg KM; Justice JM; Silver NL; Wu L; Varma S; West R; Licht JD; Zajac-Kaye M; Kentsis A; Kaye FJ
Oral Oncol; 2019 Nov; 98():147-155. PubMed ID: 31606723
[TBL] [Abstract][Full Text] [Related]
33. Integrated transcriptomic and epigenetic data analysis identifiesaberrant expression of genes in acute myeloid leukemia with MLL‑AF9 translocation.
Wang F; Li Z; Wang G; Tian X; Zhou J; Yu W; Fan Z; Dong L; Lu J; Xu J; Zhang W; Liang A
Mol Med Rep; 2020 Feb; 21(2):883-893. PubMed ID: 31789407
[TBL] [Abstract][Full Text] [Related]
34. Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia.
Ghisi M; Kats L; Masson F; Li J; Kratina T; Vidacs E; Gilan O; Doyle MA; Newbold A; Bolden JE; Fairfax KA; de Graaf CA; Firth M; Zuber J; Dickins RA; Corcoran LM; Dawson MA; Belz GT; Johnstone RW
Cancer Cell; 2016 Jul; 30(1):59-74. PubMed ID: 27374225
[TBL] [Abstract][Full Text] [Related]
35. The leukemogenic fusion gene MLL-AF9 alters microRNA expression pattern and inhibits monoblastic differentiation via miR-511 repression.
Fleischmann KK; Pagel P; von Frowein J; Magg T; Roscher AA; Schmid I
J Exp Clin Cancer Res; 2016 Jan; 35():9. PubMed ID: 26762252
[TBL] [Abstract][Full Text] [Related]
36. New tricks from an old oncogene: gene fusion and copy number alterations of MYB in human cancer.
Stenman G; Andersson MK; Andrén Y
Cell Cycle; 2010 Aug; 9(15):2986-95. PubMed ID: 20647765
[TBL] [Abstract][Full Text] [Related]
37. The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells.
Zhao H; Kalota A; Jin S; Gewirtz AM
Blood; 2009 Jan; 113(3):505-16. PubMed ID: 18818396
[TBL] [Abstract][Full Text] [Related]
38. Myb controls intestinal stem cell genes and self-renewal.
Cheasley D; Pereira L; Lightowler S; Vincan E; Malaterre J; Ramsay RG
Stem Cells; 2011 Dec; 29(12):2042-50. PubMed ID: 21997934
[TBL] [Abstract][Full Text] [Related]
39. RUNX1 is required for oncogenic
Choi A; Illendula A; Pulikkan JA; Roderick JE; Tesell J; Yu J; Hermance N; Zhu LJ; Castilla LH; Bushweller JH; Kelliher MA
Blood; 2017 Oct; 130(15):1722-1733. PubMed ID: 28790107
[TBL] [Abstract][Full Text] [Related]
40. Absence of the Shb gene in mixed-lineage leukemia MLL-AF9 cells increases latency in mice despite higher proliferation rates in vitro.
Jamalpour M; Bergquist E; Welsh M
Exp Cell Res; 2020 Dec; 397(2):112368. PubMed ID: 33220260
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
